57
Views
0
CrossRef citations to date
0
Altmetric
Erratum

Erratum

Pages 1115-1116 | Published online: 01 Jul 2016
This article refers to:
Retraction: Inhibition of CTCF-Regulated miRNA-185-5p Mitigates Renal Interstitial Fibrosis of Chronic Kidney Disease

Following the publication of volume 17, issue 6 of Pharmacogenomics, it has been brought to our attention that the article order was incorrect.

The incorrect page numbers were previously:

  • A Calcagno, G Di Perri & S Bonora. What do we know about tailoring treatment with tenofovir? Pharmacogenomics 17(6), 531–534 (2016).

  • SB Haga & J Moaddeb. Proposal for a pharmacogenetics certificate program for pharmacists. Pharmacogenomics 17(6), 535–539 (2016).

  • T Bellon, E Ramirez, AM Borobia et al. The HLA-B*15:02 allele in a Spanish Romani patient with carbamazepine-induced Stevens–Johnson syndrome. Pharmacogenomics 17(6), 541–545 (2016).

  • A Hahn, T Fukuda, D Hahn et al. Pharmacokinetics and pharmacogenomics of β-lactam-induced neutropenia. Pharmacogenomics 17(6), 547–559 (2016).

  • J Cusato, S Allegra, S De Francia et al. Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics 17(6), 561–572 (2016).

  • MACSM Borba, RP Melo-Neto, GM Leitão et al. Evaluating the impact of missenses mutations in CYP2D6*7 and CYP2D6*14A: does it compromise tamoxifen metabolism? Pharmacogenomics 17(6), 573–582 (2016).

  • M Leusink, AH Maitland-van der Zee, B Ding et al. A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. Pharmacogenomics 17(6), 583–591 (2016).

  • D Riddle, M Gregoski, K Baker et al. Impressions of pharmacogenomic testing among Certified Registered Nurse Anesthetists: a mixed-method study. Pharmacogenomics 17(6), 593–602 (2016).

  • JK Mukonzo, RK Bisaso, J Ogwal-Okeng et al. CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. Pharmacogenomics 17(6), 603–613 (2016).

  • W Brian, LM Tremaine, M Arefayene et al. Assessment of drug-metabolism enzyme and transporter-pharmacogenetics in drug discovery and early development: perspectives of the I-PWG. Pharmacogenomics 17(6), 615–631 (2016).

  • LM Roy, RM Zur, E Uleryk et al. Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers. Pharmacogenomics 17(6), 633–656 (2016).

The page numbers are now corrected to:

  • A Calcagno, G Di Perri & S Bonora. What do we know about tailoring treatment with tenofovir? Pharmacogenomics 17(6), 531–534 (2016).

  • SB Haga & J Moaddeb. Proposal for a pharmacogenetics certificate program for pharmacists. Pharmacogenomics 17(6), 535–539 (2016).

  • T Bellon, E Ramirez, AM Borobia et al. The HLA-B*15:02 allele in a Spanish Romani patient with carbamazepine-induced Stevens–Johnson syndrome. Pharmacogenomics 17(6), 541–545 (2016).

  • A Hahn, T Fukuda, D Hahn et al. Pharmacokinetics and pharmacogenomics of β-lactam-induced neutropenia. Pharmacogenomics 17(6), 547–559 (2016).

  • MACSM Borba, RP Melo-Neto, GM Leitão et al. Evaluating the impact of missenses mutations in CYP2D6*7 and CYP2D6*14A: does it compromise tamoxifen metabolism? Pharmacogenomics 17(6), 561–570 (2016).

  • J Cusato, S Allegra, S De Francia et al . Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics 17(6), 571–582(2016).

  • M Leusink, AH Maitland-van der Zee, B Ding et al. A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. Pharmacogenomics 17(6), 583–591 (2016).

  • D Riddle, M Gregoski, K Baker et al. Impressions of pharmacogenomic testing among Certified Registered Nurse Anesthetists: a mixed-method study. Pharmacogenomics 17(6), 593–602 (2016).

  • JK Mukonzo, RK Bisaso, J Ogwal-Okeng et al. CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. Pharmacogenomics 17(6), 603-613 (2016).

  • W Brian, LM Tremaine, M Arefayene et al. Assessment of drug-metabolism enzyme and transporter-pharmacogenetics in drug discovery and early development: perspectives of the I-PWG. Pharmacogenomics 17(6), 615–631 (2016).

  • LM Roy, RM Zur, E Uleryk et al. Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers. Pharmacogenomics 17(6), 633–656 (2016).

The Editors of Pharmacogenomics would like to sincerely apologise for any inconvenience this may have cuased our readers.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.